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ABSTRACT
Antimicrobial stewardship in the UK has
evolved dramatically in the last 15 years.
Factors driving this include initial central
funding for specialist pharmacists and
mandatory reductions in healthcare-associated
infections (particularly Clostridium difficile
infection). More recently, the introduction of
national stewardship guidelines, and an
increased focus on stewardship as part of the
UK five-year antimicrobial resistance strategy,
have accelerated and embedded developments.
Antimicrobial pharmacists have been
instrumental in effecting changes at an
organizational and national level. This article
describes the evolution of the antimicrobial
pharmacist role, its impact, the progress toward
the actions listed in the five-year resistance
strategy, and novel emerging areas in
stewardship in the UK.
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THE DEVELOPMENT
OF ANTIMICROBIAL STEWARDSHIP
IN THE UK: EARLY DAYS
AND DRIVERS
In the early part of this century, the UK
government focused heavily on reducing the
incidence of healthcare-associated infections
(HCAIs) [1, 2], such as methicillin-resistant
Staphylococcus aureus (MRSA) bacteremias and
Clostridium difficile infections (CDI). A
combination of voluntary, followed by
mandatory, reporting of these infections
allowed the National Health Service (NHS) to
identify and monitor the scale of the problem,
and then to develop actions to improve
outcomes [3]. The peak incidence of MRSA
bacteremias was seen in 2003, at 7700 cases,
and for CDI the peak was seen in 2007, with
57,247 cases reported [4]. In response to these
high levels, NHS hospital Trusts were set targets
(with large financial penalties for failure) to
reduce MRSA bacteremias by 50% by 2008 and
CDI by 30% by 2010–2011 [5, 6].
At around the same time, antimicrobial
stewardship (AMS) began to evolve rapidly
when, in 2003, the Department of Health
announced a three-year Hospital Pharmacy
Initiative, complete with £12 million of
funding for hospital pharmacies, aimed at
improving the monitoring and control of
anti-infectives [7], with a view to contributing
to the efforts to tackle HCAIs. This thrust
pharmacists into a key role in AMS with the
majority of this money being spent creating
antimicrobial pharmacist positions [8].
Immediate outcomes from this initiative were
widespread update and revision of local
antimicrobial guidelines, increasing interaction
between Microbiology/Infectious Diseases and
Pharmacy (leading to development of, or more
frequent, joint ward rounds), and a dramatic
increase in the provision of education and
training to healthcare professionals in prudent
antimicrobial use [8, 9]. These interventions
have been associated with improved
antimicrobial usage, reductions in length of
stay, and improved clinical outcomes (such as
reductions in CDI) [10–14], and both of the
high-level objectives for MRSA bacteremias and
CDI cases were met with 57% and 41%
reductions, respectively.
At the core of these reductions (most
obviously for CDI) was improved antibiotic
prescribing. Initial guidance documents
around management of CDI recommended
enhancing AMS, including: dedicated teams;
using narrow spectrum antibiotics for empiric
treatment where appropriate; avoiding the use
of clindamycin and second- and
third-generation cephalosporins, especially in
the elderly; and minimizing the use of
fluoroquinolones, carbapenems and prolonged
courses of aminopenicillins [15–19].
Antimicrobial pharmacists have continued to
play an integral role in developing and
managing antimicrobial guidelines, reviewing
individual patient regimens to optimize
therapy, educating healthcare staff on the
appropriate use of antimicrobials and
monitoring and auditing outcomes of
antimicrobial usage across organizations.
There has been a continued impressive 77%
reduction in CDI cases from 108 cases per
100,000 population (in 2007–2008) to 25 cases
in 2013–2014 [4]. Further developments in CDI
objective setting now include a consideration of
the avoidability of the case and whether there
have been any ‘‘lapses in care’’ leading to the
episode [20]. Although it is not discretely
defined as such, inappropriate antimicrobial
usage would be recognized as a ‘‘lapse in care’’,
and antimicrobial pharmacists continue to be
heavily involved in optimizing therapy,
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preventing CDI cases, and investigating them
and sharing relevant learning when they occur.
In Scotland, similar targets, but without
financial penalties, were set for the reduction
of S. aureus bacteremia and CDI [21] which have
resulted in similar significant reductions to
those seen in England [22]. The national
stewardship program led by Scottish
Antimicrobial Prescribing Group (SAPG) has
brought about reduced use of antibiotics
associated with a high risk of CDI and this is
acknowledged as a major factor in reducing the
CDI rate [23].
MORE RECENT DEVELOPMENTS
IN UK STEWARDSHIP GUIDELINES
AND STRATEGY
To better develop and standardise the
stewardship strategy, official guidance and
toolkits have recently been issued in the UK
for community (primary) care in 2012 [24] and
hospital (secondary) care, firstly in 2011 and
very recently updated in 2015 [25, 26].
In 2013, a cross-government five-year
antimicrobial resistance (AMR) strategy was
published which takes a ‘One Health’
approach to tackling AMR [27]. This outlined
seven key areas for action (Table 1) and
recommended that, for the first time, an
implementation plan and yearly progress
reports be published. As healthcare in the UK
is devolved into four different national services
(England, Scotland, Wales and Northern
Ireland) each nation has a committee, which
oversees stewardship (Table 2). These groups are
largely responsible for ensuring progress toward
the AMR strategy and all have significant
pharmacist input.
To date, antimicrobial pharmacists have had
most involvement in three of the key areas
highlighted in the UK AMR strategy, which are
discussed in detail below. Antimicrobial
pharmacists have a smaller role in infection
prevention and control by providing
pharmaceutical expertise to infection control
committees and infection prevention and
control teams. Also, increasing work is being
carried out to improve the evidence base
through research into stewardship and to
strengthen UK and international collaboration.
Developing new compounds or vaccines for use
in clinical practice, and the introduction of
other diagnostics and treatments is usually
beyond the remit of their work.
Better Access To, and Use of, Surveillance
Data
Feedback of consumption data is a key element
of an AMS program [28]. In order to engage
prescribers, data are needed [29] and lack of it is
a barrier to effective implementation of AMS
[30, 31]. In the UK, consumption data have
been available since 1991 for community
prescribers. It is captured as part of the
reimbursement of community pharmacists for
dispensing NHS prescriptions [32], but will not
include antibiotics supplied by any other
Table 1 UK antimicrobial resistance strategy: seven key
areas for action
Better access to and use of surveillance data
Optimizing prescribing practice
Improving infection prevention and control
Improving professional education, training and public
engagement
Improving the evidence base through research
Developing new drugs, vaccines and other diagnostics
and treatments
Strengthening UK and international collaboration
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method, e.g. private prescriptions or packs
given out in clinics. The data are used to
compare rates of prescribing within localities
using a standardized method to account for
differences in the local population. For
example, the use of Specific Therapeutic
Group Age–sex weightings Related Prescribing
Units (STAR-PUs) as a denominator allows more
accurate and meaningful comparisons within a
specific therapeutic group by taking into
account the types of people who will be
receiving that treatment [33]. These data can
be used to drive improvements in antimicrobial
prescribing rates, total antibiotic consumption
and broad-spectrum antibiotic consumption
(cephalosporins, fluoroquinolones and
amoxicillin/clavulanate) [34, 35]. From 2005
until 2013, overall antimicrobial consumption
had been increasing in the community, but
significant reductions were seen in the use of
cephalosporins and fluoroquinolones [32].
Although there has been no explicit linkage
between increasing AMR rates and increasing
consumption of specific antimicrobials or
classes, in 2014, the Department of Health’s
expert advisory committee, the Advisory
Committee on Antimicrobial Resistance and
Healthcare Acquired Infections (ARHAI),
Table 2 National groups responsible for the overview of stewardship
Nation Group Date
formed
Remit
England Antimicrobial Stewardship subgroup (ASG)
of the Advisory Committee on
Antimicrobial Resistance and
Healthcare-Associated Infection (ARHAI)
2003 Established as part of the Specialist Advisory
Committee on Antimicrobial Resistance
(SACAR), to focus on the prudent prescribing of
antimicrobials across the National Health Service
(NHS)
English Surveillance Program for
Antimicrobial Utilization and Resistance
(ESPAUR)
2013 Developed by Public Health England (PHE) to
bring together antimicrobial utilization and
resistance data, examine national implementation
of stewardship initiatives and develop quality
measures, methods to monitor unintended
outcomes of antimicrobial stewardship and both
public and professional behavior interventions
Scotland Scottish Antimicrobial Prescribing Group
(SAPG)
2008 To lead and coordinate delivery of the Scottish
Management of Antimicrobial Resistance Action
Plan (ScotMARAP) [83]
Wales Welsh Antimicrobial Resistance Program
Surveillance Unit (WARP-SU)
2008 Currently focuses on reporting antimicrobial usage
and resistance data and coordinating nationwide
antimicrobial audits
Northern
Ireland
Antimicrobial Resistance Action Committee
(ARAC)
2002 ARAC provides expert advice to the Department of
Health, Social Services and Public Safety
(DHSSPS) on all issues to do with antimicrobial
resistance and provides leadership on strategies for
tackling this issue. Strategy for Tackling
Antimicrobial Resistance (STAR) 2012–2017 [84]
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proposed that total antimicrobial consumption
should reduce to 2010 levels in the community
[36, 37] and that the proportion of antibiotics
from cephalosporin, quinolone or
amoxicillin/clavulanate classes should reduce
by 10% from the 2013/2014 value or to less
than the 2013/2014 median, whichever is the
smaller reduction. In 2015–2016, a Quality
Premium [38] (financial reward) was
introduced to achieve this goal, along with a
national reporting tool to monitor it [39].
In Scotland, a similar national quality
indicator was introduced in 2013 aimed at
reducing unnecessary antibiotic use for
self-limiting respiratory infections. This uses a
‘best in class’ approach so that at least 50% of
practices in each region will be at or below the
25th percentile of Scottish practices (using
January–March 2013 as the baseline) or will
have made the minimum acceptable reduction
toward that level. In 2013–2014, there were
276,383 (6.5%) fewer prescriptions for systemic
antibacterials in primary care in Scotland than
in 2012–2013 and 57.5% of practices achieved
the national quality indicator. Since 2008, there
has been a focus on reducing the use of
cephalosporins, quinolones and
amoxicillin/clavulanate in the community and
this has led to year-on-year reductions in the
use of these agents [40].
For English hospitals, a detailed and
comprehensive report published by the English
Surveillance Program for Antimicrobial
Utilization and Resistance (ESPAUR), set up by
Public Health England in response to the
five-year AMR strategy, provided the very first
national data on antimicrobial consumption
[41]. This report covered the period 2010–2013
and used consumption data derived from
hospital pharmacy stock management systems
for drugs dispensed to both individual patients
and ward stocks. This type of data has to be used
because electronicprescribing (EP) inhospitals in
England is very much in its infancy [41]. Using
hospital pharmacy stock management systems
prevents the reporting of detailed consumption
data down to doctor or clinical team level, and
neither of the two main pharmacy accounting
systems used in the UK includes a reporting tool
as standard. A worldwide survey of hospital AMS
showed that 92% of UK hospitals reported
antimicrobial usage data, but only 52%
reported defined daily doses (DDDs) to specialty
level, and even fewer were able to link
consumption data to resistance or infection
rates (31% and 33%, respectively) [42, 43].
The ESPAUR report [41] showed an increase
in overall antibiotic consumption in hospital
inpatients of 11.9% over the 4-year period (an
average year-on-year increase of 3.5%,
equivalent to 2.3–2.5 DDD per 1000
inhabitants per day). The data were reported at
area level only, so did not allow benchmarking
between hospitals.
ARHAI in England also proposed (although
these proposals may be subject to further
refinement) that total antibiotic consumption
be reduced by 1% per annum over 2015–2019
(as measured by DDD per 1000 admissions per
year), and total carbapenem consumption be
reduced to 2010 consumption levels (as
measured by the same method), corresponding
to an average reduction of 20–25% [36, 37].
Again, there has been no explicit linkage
between increasing antimicrobial consumption
and increasing AMR, but the ESPAUR report
does show increases in both elements over the
reporting period, and controlling antimicrobial
consumption is recognized as a key element of
the AMR strategy [41]. In 2015–2016,
consumption data are being validated by
hospitals as part of the Quality Premium [38].
In addition, 65% of NHS hospitals are also using
a specific software package (Rx-Info Define) to
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benchmark hospital medicines consumption
[44].
Since 2008, SAPG has published annual
reports on antimicrobial use and resistance in
humans [45] utilizing national data marts which
collate data from hospital Pharmacy and
Microbiology systems and prescriptions for
antibiotics dispensed by community
pharmacists. In Wales, the Welsh Antimicrobial
Resistance Program Surveillance Unit (WARP-SU)
[46] currently reports antimicrobial usage and
resistance data. Finally, within Northern Ireland,
the COMPASS system [47] provides data on
primary care antibiotic prescribing with the
national AMR dataset currently being developed.
Optimizing Prescribing Practice
There are two national AMS toolkits for England:
Start Smart then Focus for hospital care [25, 26]
and the Treat Antibiotics Responsibly, Guidance,
Education, Tools (TARGET) Antibiotics toolkit
for community care [24]. Wales [48] and
Scotland [49] have their own versions of the
guidance. In addition, national guidance on
AMS is due for publication in August 2015 by
the National Institute for Health and Care
Excellence (NICE) [50].
The Scottish Antimicrobial Prescribing
Group has produced national guidance [49] on
AMS and infection management to support
antimicrobial teams and prescribers across
hospital and community care settings. All
regions have a centrally funded antimicrobial
pharmacist position in addition to locally
funded positions to support local delivery of
stewardship and drive quality improvement in
antimicrobial prescribing.
A large proportion of antimicrobial
pharmacist time is currently dedicated to
optimizing prescribing practice, as described
later in this article.
Improving Professional Education,
Training and Public Engagement
Education and training is essential to
optimizing prescribing and AMS, and, in order
to drive consistency in practice, performance
standards need to be set. The first national
antimicrobial prescribing and stewardship
competences were published in 2013 and
these are currently being developed to include
in Health Education England work streams [51].
The competences consist of five dimensions,
and each dimension includes statements that
describe the activity and outcomes that
prescribers should be able demonstrate. The
five dimensions are:
1. Infection prevention and control.
2. AMR and antimicrobials.
3. The prescribing of antimicrobials.
4. AMS.
5. Monitoring and learning.
Antimicrobial pharmacists are central to the
delivery of education on stewardship for
healthcare staff, and in 2014 an expert
curriculum [52] was developed to support
specialist Infectious diseases and antimicrobial
pharmacists in this role, as well as providing
professional development opportunities. The
4-year pharmacy degree contains variable
amounts of teaching and training in AMS and
there are limited postgraduate opportunities for
pharmacists to gain specialist training in
infection management and AMS [53]. The
expert curriculum provides the first
opportunity to develop some form of
credentialing in this area.
The TARGET antibiotic toolkit [24] includes
educational materials for prescribers in primary
care. A similar initiative has also been
developed in Wales: the ‘Stemming the Tide of
Antibiotic Resistance’ educational program
(STAR) [54, 55]. This includes resources for
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clinicians to share with the public during
consultations and is reported to have helped
deliver changes in local prescribing practices
and reduce unnecessary antibiotic use [56]. In
Scotland, a similar program, the Scottish
Reduction in Antimicrobial Prescribing
(ScRAP) [57], was launched in October 2013 as
an educational resource to help prescribers to
meet a government target to reduce
unnecessary prescribing of antibiotics. In 2015,
SAPG, in collaboration with NHS Education for
Scotland, launched a stewardship resource for
nurses and midwives in the form of an
interactive electronic workbook [58].
Since 2008, the UK has actively promoted
‘European Antibiotic Awareness Day’ (EAAD)
which is held in November each year to raise
awareness among health professionals and the
public of AMR and appropriate prescribing and
antimicrobial use. In 2014, to move from
raising awareness to engagement, and as a
marker for behavior change, a new campaign,
Antibiotic Guardian, was developed which
called on everyone in the UK to choose a
pledge on the website http://www.
antibioticguardian.com. The pledges were
developed using the behavior change strategy
‘if–then’ approach. In the first two months,
11,998 healthcare professionals and members of
the public chose a pledge and became antibiotic
guardians.
HOW DOES THE PHARMACIST
FUNCTION WITHIN STEWARDSHIP
TEAMS?
In 2011, English hospitals reported employing
an average of one full-time antimicrobial
pharmacist per 776 inpatient beds,
representing approximately 3% of the clinical
pharmacists in those organizations [59]. These
pharmacists vary in seniority, and often
combine their antimicrobial duties with other
responsibilities such as respiratory or intensive
care specialist roles [59]. The typical activities of
antimicrobial pharmacists in hospitals have
been well described in the literature, and are
shown in Table 3 [8, 9, 41, 59–62]. Key to all of
Table 3 Typical activities of UK antimicrobial pharmacists
Production and dissemination of evidence-based prescribing guidelines and prescribing policies, increasingly utilizing
technology such as smartphone ‘apps’ and electronic training packages
Education of prescribers, pharmacy and nursing staff in the prudent use of antimicrobials, including mandatory
induction training for all staff
Providing a clinical advice service, often with access via a pager, supporting prescribers in optimizing antimicrobial
therapy for individual patients, and providing input on multidisciplinary infection ward rounds
Advising on therapeutic drug monitoring for antimicrobials
Monitoring and feedback of trends in antimicrobial prescribing, formulary and guideline adherence to clinical teams, and
inputting into governance structures within organization. Point prevalence surveys of antimicrobial use, conducted at
least annually, are widespread in the UK, though an increasing number of hospitals are using rapid feedback of quality
indicator measures to drive improvements in antimicrobial prescribing [14]
Managing entry of new antimicrobials onto hospital formularies, including critical review of new agents and their place in
therapy
Clinical research, both in support of drug registration studies, and in novel research to consolidate the evidence base
around antimicrobial stewardship
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this activity is the well-established linkage
between AMS pharmacists and their
microbiologist/infectious diseases colleagues,
which allows both specialties to share and
contribute to optimizing patient care. Also,
due to the patient load and their other
responsibilities, antimicrobial pharmacists in
the UK rely heavily on contributions from
their hospital pharmacy colleagues to deliver
the fundamentals of AMS (following
appropriate education and training from the
specialist pharmacists themselves), and also to
identify patients that require more specialist
input. However, although these activities are
well-described, good-quality evidence of their
impact on optimizing antimicrobial therapy
and patient outcomes is sadly lacking.
Improving this evidence-base forms one of the
future aspirations of the specialty, utilizing
upcoming developments in data capture to
take this forward (see below).
In comparison to the hospital sector, there
are very few dedicated antimicrobial specialist
pharmacist roles in primary care in the UK. A
survey carried out in 2014 identified that, in
66% of primary care organizations, AMS roles
were led by generalist prescribing advisors/
medicine management pharmacists [63]. AMS
activities of pharmacists in primary care are
similar to those in secondary care in respect to
guideline writing, audit, education, monitoring
and feedback; often teams link with hospital
microbiology laboratories for clinical infection
advice. Given that over 85% of antimicrobials
are prescribed outside the hospital sector in the
UK [41], and with the increasing emphasis on a
‘One Health’ approach to tackling AMR [27],
cross-sector AMS programs, where primary and
secondary care specialists work together to
improve prescribing across a regional
population, are likely to become the norm
over the coming years. There are already some
examples of cross-sector working in select
regions of the UK, where specialist
antimicrobial pharmacists from both sectors
work on collaborative projects to improve
antimicrobial use.
In Scotland, antimicrobial pharmacists have
a remit for hospital and community care and
work closely with prescribing advisers to
influence general practitioners antibiotic
prescribing behaviors. The national network of
antimicrobial pharmacists works closely with
SAPG to support the national stewardship
program and, in addition, they have their own
annual work plan of quality improvement
initiatives.
THE CHANGING HEALTHCARE
LANDSCAPE: AN OPPORTUNITY
FOR ANTIMICROBIAL
PHARMACISTS?
Creating national infrastructures and
technologies to help support AMS
development has been important for UK
antimicrobial pharmacists and their teams.
The tools already discussed have provided
opportunities particularly at a local level for
teams to review, develop, implement and
encourage AMS strategies. However, the
challenge is how to adapt local stewardship
programs to the evolving, changing healthcare
landscape that is the NHS. Below, are a few
scenarios of where UK pharmacists are
becoming involved in more novel stewardship
activities.
Electronic Systems
Although there is an extensive literature on the
positive contribution that electronic systems
(such as computerized clinical decision support,
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computerized physician order entry or full EP)
can provide to AMS, the bulk of this originates
from the USA, South East Asia, and Australia,
where such systems have been in use for many
years [64–68]. EP is not yet widely implemented
in the UK, although a handful of pathfinder
hospitals have had experience with EP systems
for a considerable time [69]. Furthermore,
although the potential benefits from
introduction of EP have long been recognized
[70, 71], little work has so far been published on
the actual impact of these systems on
antimicrobial usage and resistance. Four small
case studies have reported on the impact of
electronic systems in AMS in the UK [72–75]
demonstrating decreased levels of antimicrobial
usage [72], increased identification of patients
requiring intervention [73], avoidance of
clinically significant drug interactions [74] and
improvements in documentation of key
antimicrobial indicators (such as indication
and duration, which feature in the Start Smart,
Then Focus toolkit) [75].
Around 15 different providers of EP systems
are active within the UK market, and these
products are being used in about 20% of NHS
Trusts, with an expectation that 40–50% of
Trusts will have a plan for implementation of EP
in place by 2016 [76]. With this large number of
different solutions and timelines for
implementation, there will inevitably be
significant variation in how EP is used to
support AMS. There is an on-going research
program investigating how EP is introduced
into NHS Trusts which will include work
looking at effectiveness (primarily safety
considerations around drug–drug interactions
or allergy awareness) and outcomes [76]. Work
is beginning, with the formation of ESPAUR, to
help guide NHS Trusts in their procurement and
implementation plans for EP, with specific
reference to their use in AMS. It is to be
expected that, as EP systems and their use in
stewardship matures within the UK, an
increasing evidence base will become available,
highlighting additional beneficial outcomes
(and potential pitfalls).
A further step change in the benefits of EP for
stewardship will be achieved by
implementation of mobile technologies
harnessing EP, biochemical and
microbiological results, patient observations,
radiology, and clinical decision support in a
single point-of-care device. There are a large
number of antimicrobial smartphone apps
available within the UK, commonly providing
information on preferred antimicrobial choices
for specific indications, but, as this field also
matures, the exciting possibilities provided by
linking these apps with the many data sources
available to support clinical decision making
will drive innovation and research in this area.
Antifungal Stewardship Initiatives
Despite the low incidence of invasive fungal
infections compared to bacterial infections, for
some specialist centers antimicrobial
expenditure is dominated by antifungal use.
While strategies have focused on the prudent
use of antibiotics, antifungal stewardship is less
well defined. This is primarily due to a lack of
effective diagnostics to guide therapy, of
therapeutic drug monitoring to guide dosing
and of knowledge of the funding arrangements
for antifungals. Antifungal stewardship
initiatives are gaining momentum in the UK
at present with pharmacists driving the agenda.
One such program [77] has suggested savings of
approximately £180,000 over a 12-month
period by rationalizing and reviewing
therapies, while another two programs [77, 78]
found stepping down and stopping unnecessary
empiric therapy was common.
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Outpatient Parenteral Antimicrobial
Therapy
Over recent years, there has been a drive to treat
patients closer to their own home, facilitating
early discharge or even avoiding admission
altogether. For antimicrobials, outpatient
parenteral antimicrobial therapy (OPAT) offers
a safe and effective (clinically and financially)
[79] means to deliver treatment outside the
inpatient setting, providing good clinical
governance and AMS practices are in place [80,
81]. Pharmacists have been cited as core
members of the OPAT team in both the adult
and pediatric UK OPAT good practice
recommendations [81, 82]. This has led to a
number of pharmacists taking national roles in
this area, particularly addressing the
stewardship dilemma that OPAT presents
where the convenience of dosing
antimicrobials to suit OPAT may take
precedence over the spectrum of activity [80].
SUMMARY
In summary, antimicrobial pharmacists in the
UK have significantly increased in number and
greatly contributed to large reductions in
selected HCAIs over the last decade. They are
also instrumental in meeting the actions set out
by the UK AMR Strategy, with significant
progress made toward several of the key areas
for action. Improving the evidence base
through research, developing novel
stewardship strategies and strengthening
national and international networks are areas
where UK antimicrobial pharmacists must
concentrate their efforts in the coming years.
We look forward to working collaboratively
with a wider, international, group of
colleagues in the future.
ACKNOWLEDGMENTS
This supplement was not sponsored by outside
commercial interests. No source of funding was
received for publication of this article. All
named authors meet the International
Committee of Medical Journal Editors (ICMJE)
criteria for authorship for this manuscript, take
responsibility for the integrity of the work as a
whole, and have given final approval to the
version to be published. All authors were
involved in writing this manuscript.
Conflict of interest. M.G. serves on the
BSAC UK OPAT Initiative Steering Group.
M.G. receives reimbursement of travel
expenses only from the BSAC for attending
and speaking at the UK OPAT Workshop Series
and related events. M.G. reports attending
advisory boards for The Medicines Company,
Clinigen, Astellas Pharmaceuticals and Cubist/
Merck and receiving educational travel and
speaker grants from Eumedica Pharmaceuticals
and Astellas Pharmaceuticals, Sanofi,
respectively. P.W. has received fees for
advisory boards, speaker honoraria or
educational grants from Astellas
Pharmaceuticals, Baxter, Clinigen, Cubist,
Eumedica, ICNet, and Pfizer. D.A.O reports
attending advisory boards for Cubist and
Merck Sharpe Dome (unpaid/paid to
organization) and speaker honorarium to
Antimicrobial Pharmacists training program
led by antimicrobials pharmacists, supported
by Astellas Pharmaceuticals. P.H. reports
attending advisory boards for Astellas
Pharmaceuticals, Baxter/ICNET, Cubist/Merck,
Gilead, GSK, Novartis, Pfizer, Sanofi and
receiving educational travel and speaker grants
from Astellas Pharmaceuticals B.Braun,
Eumedica Pharmaceuticals, Gilead. J.S.
S60 Infect Dis Ther (2015) 4 (Suppl 1):S51–S64
received a speaker honorarium from bioMerieux
UK for a national Microbiology meeting. L.W.
has received fees for advisory boards, speaker
honoraria or travel expenses from Astellas
Pharmaceuticals, Cubist/Merck, Gilead, Pfizer,
and UKCPA. H.W. has received fees for
consultancy, advisory boards or travel
expenses from Astellas Pharmaceuticals,
AstraZeneca, Basilea/Quintiles, Bayer, Cubist/
MSD, Roche, Pfizer, UKCPA, ECDC and BSAC.
Compliance with ethics guidelines. This
article does not contain any new studies with
human or animal subjects performed by any of
the authors.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommer-
cial use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Department of Health. Getting ahead of the curve:
a strategy for combating infectious diseases
(including other aspects of health protection).
2002.
2. Department of Health. Winning ways: working
together to reduce healthcare associated infection
in England. 2003.
3. National Audit Office. Reducing healthcare
associated infections in hospitals in England. 2009.
4. Department of Health. Annual epidemiological
commentary: mandatory MRSA, MSSA and E. coli
bacteraemia and C. difficile infection data. 2013/14.
5. Department of Health. Bloodborne MRSA
infections rates to be halved by 2008. http://
webarchive.nationalarchives.gov.uk/?/www.dh.
gov.uk/en/Publicationsandstatistics/Pressreleases/
DH_4093533.
6. Department of Health. The operating framework for
the NHS in England 2008/09 http://webarchive.
nationalarchives.gov.uk/20130107105354/http://
www.dh.gov.uk/prod_consum_dh/groups/dh_dig
italassets/@dh/@en/documents/digitalasset/dh_08
1271.pdf.
7. Department of Health. PL CMO (2003) 3: Hospital
Pharmacy initiative for promoting prudent use of
antibiotics in hospitals. 2003.
8. Wickens HJ, Jacklin A. Impact of the hospital
pharmacy Initiative for promoting prudent use of
antibiotics in hospitals in England. J Antimicrob
Chemother. 2006;58:1230–7.
9. Hand K. Antibiotic pharmacists in the ascendancy.
J Antimicrob Chemother. 2007;60(Suppl 1):i73–6.
10. Ansari F, Gray K, Nathwani D, et al. Outcomes of an
intervention to improve hospital antibiotic
prescribing: interrupted time series with
segmented regression analysis. J Antimicrob
Chemother. 2003;52:842–8.
11. Wickens HJ, Robson R, Griffiths T. A web-based
pharmacy to microbiology referral system. Hosp
Pharm. 2006;13:131–2.
12. Weeks C, Jones G, Wylie S. Costs and health care
benefits of an antimicrobial management
programme. Hosp Pharm. 2006;13:179–82.
13. Talpaert MJ, Rao GG, Cooper BS, Wade PA. Impact
of guidelines and enhanced antibiotic stewardship
on reducing broad-spectrum antibiotic usage and
its effect on incidence of Clostridium difficile
infection. J Antimicrob Chemother.
2011;66:2168–74.
14. Thakkar K, Gilchrist M, Dickinson E, Benn J,
Franklin BD, Jacklin A, et al. A quality
improvement programme to increase compliance
with an anti-infective prescribing policy.
J Antimicrob Chemother. 2011;66:1916–20.
15. Department of Health. Saving lives—high impact
intervention. Care bundle to reduce Clostridium
difficile. 2007.
16. Department of Health. Clostridium difficile
infection: how to deal with the problem. 2008.
17. Public Health England. Clostridium difficile: what it
is, how to prevent, how to treat. 2009.
18. Health Protection Agency. Clostridium difficile
infection (CDI): management in care homes. 2010.
Infect Dis Ther (2015) 4 (Suppl 1):S51–S64 S61
19. Department of Health. Clostridium difficile:
updated guidance on diagnosis and reporting.
2012.
20. NHS England. Clostridium difficile infection
objectives for NHS organisations in 2014/15 and
guidance on sanction implementation.
21. NHSScotland Performance. HEAT Targets due for
delivery 2006/07–2014/15. http://www.gov.scot/
Resource/0046/00467027.pdf.
22. Health Protection Scotland. Commentary of
quarterly epidemiological data on Clostridium
difficile infection (CDI) and Staphylococcus aureus
bacteraemias (SAB) in Scotland. January to March
(Q1) 2015. http://www.documents.hps.scot.nhs.uk/
hai/sshaip/publications/quarterly-epidemiological-
commentaries/2015/2015-q1-sab-cdi-commentary.
pdf.
23. Scottish Antimicrobial Prescribing Group. Progress
report for 2008–2011. https://www.scottishmedi
cines.org.uk/files/sapg/SAPG_Progress_Report_2008-
11.pdf.
24. Royal College of General Practitioners. TARGET
Antibiotics Toolkit [cited 2015 15/07/2015]. http://
www.rcgp.org.uk/clinical-and-research/target-anti
biotics-toolkit.aspx.
25. Department of Health. Antimicrobial stewardship:
Start smart—then focus. 2011.
26. Public Health England. Start smart—then focus:
antimicrobial stewardship toolkit for English
hospitals. 2015.
27. Department of Health. Annual progress report and
implementation plan (2014) of the UK AMR
Strategy 2013–18. 2014.
28. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN,
Weinstein RA, Burke JP, et al. Infectious Diseases
Society of America and the Society for Healthcare
Epidemiology of America guidelines for developing
an institutional program to enhance antimicrobial
stewardship. Clin Infect Dis. 2007;44(2):159–77.
29. Dumartin C, Rogues AM, Amadeo B, Pefau M,
Venier AG, Parneix P, et al. Antibiotic usage in
south-western French hospitals: trends and
association with antibiotic stewardship measures.
J Antimicrob Chemother. 2011;66(7):1631–7.
30. Fridkin SK, Srinivasan A. Implementing a strategy
for monitoring inpatient antimicrobial use among
hospitals in the United States. Clin Infect Dis.
2014;58(3):401–6.
31. Chen AW, Khumra S, Eaton V, Kong DC. Snapshot
of barriers to and indicators for antimicrobial
stewardship in Australian Hospitals. J Pharm Pract
Res. 2011;41(1):37–41.
32. NHS Business Services Authority. http://www.
nhsbsa.nhs.uk/Index. Accessed Aug 2015.
33. Health and Social Care Information Centre.
Prescribing measures, indicators and comparators.
2015. http://www.hscic.gov.uk.
34. Health and Social Care InformationCentre.Medicines
Optimisation Key Therapeutic Topics Comparators
2015/16. 2015. http://www.hscic.gov.uk.
35. National Institute for Health and Care Excellence.
Medicines management options for local
implementation. 2015. http://www.nice.org.uk/
Media/Default/About/what-we-do/NICE-advice/Key-
therapeutic-topics/compiled%20KTT%20Document_
final_March%202015%20amend.pdf.
36. Department of Health. ARHAI 5th Annual Report,
April 2013–March 2014. 2014. https://www.gov.uk/
government/uploads/system/uploads/attachment_
data/file/405295/ARHAI_annual_report.pdf.
37. Department of Health. Minutes of ARHAI
Twenty-Fifth Meeting on 03 July 2014. 2014.
https://app.box.com/ARHAI-Minutes-Papers/1/251
0541487/21452112235/1.
38. NHS England. Quality Premium: 2015/16 guidance
for CCGs. 2015. http://www.england.nhs.uk/wp-
content/uploads/2015/04/qual-prem-guid-1516.pdf.
39. NHS PrescQIPP. Antibiotic QP prescribing report for
2014/15 launched. http://www.prescqipp.info/news
feed/antibiotic-qp-prescribing-report-for-2014/15.
40. NHS National Services Scotland, Scottish
Antimicrobial Prescribing Group. Primary Care
Prescribing Indicators Annual Report 2013–2014.
https://isdscotland.scot.nhs.uk/Health-Topics/Pres
cribing-and-Medicines/Publications/2014-10-14/
2014-10-14-SAPG-Primary-Care-PI-2013-14-Report.
pdf?18948000670.
41. Public Health England. English surveillance
programme for antimicrobial utilisation and
resistance (ESPAUR) Report 2014. http://www.gov.
uk/government/uploads/system/uploads/attachment
_data/file/362374/ESPAUR_Report_2014__3_.pdf.
42. Howard P, Pulcini C, Levy Hara G, West RM, Gould
IM, Harbarth S, et al. An international
cross-sectional survey of antimicrobial stewardship
programmes in hospitals. J Antimicrob Chemother.
2015;70:1245–55.
43. Howard P, Pulcini C, Levy Hara G, Nathwani D,
Gould I. Global antimicrobial stewardship survey—
interim analysis of UK data. Oral paper 2087.
S62 Infect Dis Ther (2015) 4 (Suppl 1):S51–S64
Birmingham: Federation of Infection Societies;
2013.
44. Rx Info. Define—measure prescribing practices
against those of neighbouring hospitals: Rx_Info;
2015 [cited 2015 15/Jul/2015]. http://www.rx-info.
co.uk/products/define.ashx.
45. NHS National Services Scotland, Report on
Antimicrobial Use and Resistance in Humans in
2013. https://isdscotland.scot.nhs.uk/Health-Topics/
Prescribing-and-Medicines/Publications/2015-01-27/
2015-01-27-SAPG-2013-Report.pdf?86472719908.
46. Public Health Wales. Reports of the Welsh
Antimicrobial Resistance Programme. 2015.
https://www.wales.nhs.uk/sites3/page.cfm?orgId=
457&pid=28906.
47. Health Social Care Northern Ireland. COMPASS—
General Practice prescribing information service.
2015. http://www.hscbusiness.hscni.net/services/
2163.htm.
48. Public Health Wales. Antimicrobial Stewardship:
‘‘Start Smart—Then Focus’’: Guidance for
Antimicrobial Stewardship for Hospitals in Wales.
2011. http://www.wales.nhs.uk/sitesplus/documents/
888/Public%20Health%20Wales%20Antimicrobial%
20Stewardship%20Guidance.pdf.
49. Scottish Antimicrobial Prescribing Group, Quality
Improvement. http://www.scottishmedicines.org.
uk/SAPG/Quality_Improvement/Quality_Improve
ment. Accessed Aug 2015.
50. National Institute for Health and Care Excellence.
Antimicrobial Stewardship 2015. https://www.nice.
org.uk/guidance/indevelopment/gid-
antimicrobialstewardship. Accessed Aug 2015.
51. Ashiru-Oredope D, Cookson B, Fry C, on behalf of the
Advisory Committee on Antimicrobial R, Healthcare
Associated Infection Professional Education S.
Developing the first national antimicrobial
prescribing and stewardship competences.
J Antimicrob Chemother. 2014;69:2886–8.
52. Sneddon J, Gilchrist M, Wickens H. Development
of an expert professional curriculum for
antimicrobial pharmacists in the UK. J Antimicrob
Chemother. 2015;70:1277–80.
53. Wickens H, Farrell S, Jacklin A, Ashiru-Oredope D,
Holmes A. Who trains the trainer? Education of
antimicrobial pharmacists. Poster 137.
Birmingham: Federation of Infection Societies;
2013.
54. Simpson SA, Butler CC, Hood K, Cohen D, Dunstan
F, Evans MR, et al. Stemming the Tide of Antibiotic
Resistance (STAR): a protocol for a trial of a complex
intervention addressing the ‘why’ and ‘how’ of
appropriate antibiotic prescribing in general
practice. BMC Fam Pract. 2009;10:20.
55. UK Medical Research Council. The STAR
Programme (Stemming the tide of antimicrobial
resistance) 2005 [cited 2015 15/07/2015]. http://
www.stemmingthetide.org/.
56. Butler CC, Simpson SA, Dunstan F, Rollnick S,
Cohen D, Gillespie D, et al. Effectiveness of
multifaceted educational programme to reduce
antibiotic dispensing in primary care: practice
based randomised controlled trial. BMJ.
2012;344:d8173.
57. NHS Education for Scotland. Scottish Reduction in
Antimicrobial Prescribing (ScRAP) Programme.
2013. http://www.nes.scot.nhs.uk/education-and-
training/by-discipline/pharmacy/about-nes-pharm
acy/educational-resources/resources-by-topic/infec
tious-diseases/antibiotics/scottish-reduction-in-anti
microbial-prescribing-(scrap)-programme.aspx.
58. NHS Education for Scotland. Antimicrobial
stewardship educational workbook, NHS
Education for Scotland. 2015. http://www.nes.
scot.nhs.uk/media/3239839/final_antimicrobial_
stewardship_workbook.pdf.
59. Wickens HJ, Farrell S, Ashiru-Oredope DA, Jacklin
A, Holmes A, In collaboration with the
Antimicrobial Stewardship Group of Department
of Health Advisory Committee on Antimicrobial
Resistance and Health Care Associated Infections
(ASG-ARHAI). The increasing role of pharmacists in
antimicrobial stewardship in English hospitals.
J Antimicrob Chemother. 2013;68(11):2675–81.
60. Jepson A, Wickens H. What does a microbiology
pharmacist do? Pharm J. 2003;271:774–5.
61. Knox K, Lawson W, Dean B, Holmes A.
Multidisciplinary antimicrobial management and
the role of the infectious diseases pharmacist—a UK
perspective. J Hosp Infect. 2003;53(2):85–90.
62. Standing Medical Advisory Committee, Sub-Group
on Antimicrobial Resistance. The path of least
resistance. Department of Health; 1998. http://
webarchive.nationalarchives.gov.uk/20080905234
748/dh.gov.uk/en/publicationsandstatistics/publi
cations/publicationspolicyandguidance/dh_4009
357.
63. Ashiru-Oredope D. A survey of primary care
antimicrobial pharmacists. Royal Pharmaceutical
Socety conference; 2015.
64. Kullar R, Goff DA. Transformation of antimicrobial
stewardship programs through technology and
Infect Dis Ther (2015) 4 (Suppl 1):S51–S64 S63
informatics. Infect Dis Clin N Am.
2014;28(2):291–300.
65. McGregor JC, Weekes E, Forrest GN, Standiford HC,
Perencevich EN, Furuno JP, et al. Impact of a
computerized clinical decision support system on
reducing inappropriate antimicrobial use: a
randomized controlled trial. J Am Med Inform
Assoc. 2006;13(4):378–84.
66. Wang HY, Lu CL, Wu MP, Huang MH, Huang YB.
Effectiveness of an integrated CPOE
decision-supporting system with clinical
pharmacist monitoring practice in preventing
antibiotic dosing errors. Int J Clin Pharmacol
Ther. 2012;50(6):375–82.
67. Sintchenko V, Coiera E, Gilbert GL. Decision
support systems for antibiotic prescribing. Curr
Opin Infect Dis. 2008;21(6):573–9.
68. Buising KL, Thursky KA, Robertson MB, Black JF,
Street AC, Richards MJ, et al. Electronic antibiotic
stewardship–reduced consumption of
broad-spectrum antibiotics using a computerized
antimicrobial approval system in a hospital setting.
J Antimicrob Chemother. 2008;62(3):608–16 (65).
69. Baysari MT, Oliver K, Egan B, Li L, Richardson K,
Sandaradura I, et al. Audit and feedback of
antibiotic use: utilising electronic prescription
data. Appl Clin Inform. 2013;4(4):583–95.
70. Audit Commission. A spoonful of sugar: medicines
management in NHS hospitals. 2001.
71. Hitchen L. Electronic prescribing needed in
hospitals to monitor use of antibiotics. BMJ.
2007;334(7596):712.
72. Curtis C, Marriott J, Langley C. Development of a
prescribing indicator for objective quantification of
antibiotic usage in secondary care. J Antimicrob
Chemother. 2004;54(2):529–33.
73. Jumaa P, Young I, Nightingale P, Clark I. Audit of
the antimicrobial treatment of Clostridium difficile
toxin-positive episodes using an integrated
electronic prescribing, information and
communication system. J Hosp Infect. 2009;72(4):
371–3.
74. Bignardi GE, Hamson C, Chalmers A. Can we use
electronic prescribing to reduce prescription errors
for antibiotics? J Infect. 2010;61(5):427–8.
75. Cooley N. Personal communication (via Paul Wade)
on benefits of e-prescribing from lead antimicrobial
pharmacist. London: Chelsea & Westminster NHS
Foundation Trust; 2014.
76. Sheikh A. Personal communication (via Paul Wade)
about level of ePrescribing in UK from Professor of
Primary Care Research & Development and Chair,
eHealth Strategy Group, University of Edinburgh.
2015.
77. Micallef C, Aliyu SH, Santos R, Brown NM,
Rosembert D, Enoch DA. Introduction of an
antifungal stewardship programme targeting
high-cost antifungals at a tertiary hospital in
Cambridge, England. J Antimicrob Chemother.
2015;70(6):1908–11.
78. Parkinson C, Gilchrist M, Armstrong-James, D,
Whitney L, Bicanic T. Sharing and developing a
consensus approach to antifungal stewardship in
London— a proof of concept (poster). Harrogate:
Federation of Infection Societies; 2014.
79. Chapman ALN, Dixon S, Andrews D, Lillie PJ, Bazaz
R, Patchett JD. Clinical efficacy and
cost-effectiveness of outpatient parenteral
antibiotic therapy (OPAT): a UK perspective.
J Antimicrob Chemother. 2009;64(6):1316–24.
80. Gilchrist M, Seaton RA. Outpatient parenteral
antimicrobial therapy and antimicrobial
stewardship: challenges and checklists.
J Antimicrob Chemother. 2015;70(4):965–70.
81. Chapman AL, Seaton RA, Cooper MA, Hedderwick
S, Goodall V, Reed C, et al. Good practice
recommendations for outpatient parenteral
antimicrobial therapy (OPAT) in adults in the UK:
a consensus statement. J Antimicrob Chemother.
2012;67(5):1053–62.
82. Patel S, Abrahamson E, Goldring S, Green H,
Wickens H, Laundy M. Good practice
recommendations for paediatric outpatient
parenteral antibiotic therapy (p-OPAT) in the UK:
a consensus statement. J Antimicrob Chemother.
2015;70(2):360–73.
83. Nathwani D, Sneddon J, Malcolm W, Wiuff C,
Patton A, Hurding S, et al. Scottish Antimicrobial
Prescribing Group (SAPG): development and
impact of the Scottish National Antimicrobial
Stewardship Programme. Int J Antimicrob Agents.
2011;38(1):16–26.
84. Social_Services_and_Public_Safety_Northern_Ireland
DoH. Antimicrobial Resistance Action Committee
(ARAC) [cited 2015 15/07/2015]. http://www.
dhsspsni.gov.uk/health_protection-antimicrobial_
resisitance.
S64 Infect Dis Ther (2015) 4 (Suppl 1):S51–S64
